表紙
市場調查報告書

血液癌症治療藥的全球市場:2019年∼2023年

Global Blood Cancer Therapeutics Market 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 810912
出版日期 內容資訊 英文 119 Pages
訂單完成後即時交付
價格
Back to Top
血液癌症治療藥的全球市場:2019年∼2023年 Global Blood Cancer Therapeutics Market 2019-2023
出版日期: 2019年02月26日內容資訊: 英文 119 Pages
簡介

白血病是兒童中最常見的癌症類型,也是兒科患者癌症死亡率最高的原因。白血病的患病率持續顯著增加。其他類型的血癌如淋巴瘤的發病率也是推動市場成長的另一個因素,導致供應商開展新領域的研究。大多數開發中藥物用於淋巴瘤和白血病,從而導致更多的供應商進入市場研究新療法。在預測期間,兒科患者中各種類型白血病的高發病率預計將成為全球血癌治療市場的主要驅動因素之一。Technavio的分析師預測,到2023年,血癌治療市場的年複合成長率將超過8%。

本報告提供全球血液癌症治療藥市場相關調查分析,市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 報告的範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 開發平台

第7章 市場區隔:各類型

  • 市場區隔:各類型
  • 比較:各類型市場規模及預測(2018年∼2023年)
  • 白血病
  • 淋巴瘤
  • 骨髓瘤
  • 市場機會:各類型

第8章 客戶形勢

第9章 地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2018年∼2023年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第10章 決策架構

第11章 成長要素與課題

  • 市場成長要素
  • 市場課題

第12章 市場趨勢

第13章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭模式

第14章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • 武田藥品工業

第15章 附錄

  • 調查方法
  • 簡稱的清單

第16章 關於TECHNAVIO

目錄
Product Code: IRTNTR30962

About this market

Leukemia is the most common type of cancer in children and also accounts for the highest mortality rate among cancers in pediatric patients. The prevalence of leukemia has been increasing at a significantly high rate. The incidence of other types of blood cancer such as lymphomas is also another factor driving the growth of the market, as it is leading to vendors conducting research on new areas. Most of the drugs are being developed for both lymphoma and leukemia, thus leading to more vendors entering the market to research on novel therapies. The high incidence of various types of leukemia in pediatric patients is expected to be one of the major drivers of the global blood cancer therapeutics market during the forecast period. Technavio's analysts have predicted that the blood cancer therapeutics market will register CAGR of over 8% by 2023.

Market Overview

Growing adoption of therapeutics

The increasing awareness about the disease, along with the increasing global incidence, is leading to more patients undergoing diagnosis and opting for treatment during the early stages of the disease. This is leading to the increasing adoption of therapeutics for the treatment. These factors are expected to result in the growth of the global blood cancer therapeutics market during the forecast period.

Adverse effects of stem cell transplantation

Bone marrow and stem cell transplantations are some of the most effective treatment options for the treatment of blood cancer types such as leukemia, multiple myeloma, and non-Hodgkin's lymphoma. Although the treatment using stem cells is highly effective for the treatment of cancer, the side effects associated with the treatment are often high. The threat of side effects of stem cell transplant is expected to continue posing a challenge to the market growth during the forecast period.

For the detailed list of factors that will drive and challenge the growth of the blood cancer therapeutics market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be fairly fragmented and with the presence of several vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Leukemia - Market size and forecast 2018-2023
  • Lymphoma - Market size and forecast 2018-2023
  • Myeloma - Market size and forecast 2018-2023
  • Market opportunity by type

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Takeda Pharmaceutical Company Limited

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations

PART 16: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Global oncology therapeutics market
  • Exhibit 02: Segments of global oncology therapeutics market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Global blood cancer therapeutics market pipeline: Overview
  • Exhibit 18: Global blood cancer therapeutics market pipeline: Overview
  • Exhibit 19: Type - Market share 2018-2023 (%)
  • Exhibit 20: Comparison by type
  • Exhibit 21: Leukemia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Leukemia - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Lymphoma - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Lymphoma - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Myeloma - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 26: Myeloma - Year-over-year growth 2019-2023 (%)
  • Exhibit 27: Market opportunity by type
  • Exhibit 28: Customer landscape
  • Exhibit 29: Market share by geography 2018-2023 (%)
  • Exhibit 30: Geographic comparison
  • Exhibit 31: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Top 3 countries in North America
  • Exhibit 34: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Top 3 countries in Europe
  • Exhibit 37: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 38: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 39: Top 3 countries in Asia
  • Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 41: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 42: Top 3 countries in ROW
  • Exhibit 43: Key leading countries
  • Exhibit 44: Market opportunity
  • Exhibit 45: Impact of drivers and challenges
  • Exhibit 46: Vendor landscape
  • Exhibit 47: Landscape disruption
  • Exhibit 48: Vendors covered
  • Exhibit 49: Vendor classification
  • Exhibit 50: Market positioning of vendors
  • Exhibit 51: Bristol-Myers Squibb Company - Vendor overview
  • Exhibit 52: Bristol-Myers Squibb Company - Business segments
  • Exhibit 53: Bristol-Myers Squibb Company - Organizational developments
  • Exhibit 54: Bristol-Myers Squibb Company - Geographic focus
  • Exhibit 55: Bristol-Myers Squibb Company - Key offerings
  • Exhibit 56: Bristol-Myers Squibb Company - Key customers
  • Exhibit 57: F. Hoffmann-La Roche Ltd - Vendor overview
  • Exhibit 58: F. Hoffmann-La Roche Ltd - Business segments
  • Exhibit 59: F. Hoffmann-La Roche Ltd - Organizational developments
  • Exhibit 60: F. Hoffmann-La Roche Ltd - Geographic focus
  • Exhibit 61: F. Hoffmann-La Roche Ltd - Segment focus
  • Exhibit 62: F. Hoffmann-La Roche Ltd - Key offerings
  • Exhibit 63: F. Hoffmann-La Roche Ltd - Key customers
  • Exhibit 64: Johnson & Johnson Services, Inc. - Vendor overview
  • Exhibit 65: Johnson & Johnson Services, Inc. - Business segments
  • Exhibit 66: Johnson & Johnson Services, Inc. - Organizational developments
  • Exhibit 67: Johnson & Johnson Services, Inc. - Geographic focus
  • Exhibit 68: Johnson & Johnson Services, Inc. - Segment focus
  • Exhibit 69: Johnson & Johnson Services, Inc. - Key offerings
  • Exhibit 70: Johnson & Johnson Services, Inc. - Key customers
  • Exhibit 71: Novartis AG - Vendor overview
  • Exhibit 72: Novartis AG - Business segments
  • Exhibit 73: Novartis AG - Organizational developments
  • Exhibit 74: Novartis AG - Geographic focus
  • Exhibit 75: Novartis AG - Segment focus
  • Exhibit 76: Novartis AG - Key offerings
  • Exhibit 77: Novartis AG - Key customers
  • Exhibit 78: Takeda Pharmaceutical Company Limited - Vendor overview
  • Exhibit 79: Takeda Pharmaceutical Company Limited - Business segments
  • Exhibit 80: Takeda Pharmaceutical Company Limited - Organizational developments
  • Exhibit 81: Takeda Pharmaceutical Company Limited - Geographic focus
  • Exhibit 82: Takeda Pharmaceutical Company Limited - Key offerings
  • Exhibit 83: Takeda Pharmaceutical Company Limited - Key customers
  • Exhibit 84: Validation techniques employed for market sizing
Back to Top